Effects Of Direct Renin Inhibition On Atherosclerotic Biomarkers In Patients With Stable Coronary Artery Disease And Type 2 Diabetes Mellitus | 13305
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
To evaluate whether the direct renin inhibitor, aliskiren, has a more favorable effect compared to amlodipine on
atherosclerotic biomarkers in patients with stable coronary artery disease and diabetes currently receiving standard secondary
Thirty eight subjects were randomly assigned initially to either aliskiren (150 mg daily) or amlodipine (5 mg daily) for
two weeks after which the dose of either medication was increased to its maximum daily dose for four additional weeks. Baseline
and six week blood samples were analyzed for changes from baseline and between treatment groups for vascular and intracellular
cell adhesion molecule (VCAM and ICAM), c-reactive protein (CRP), nitric oxide (NO), plasminogen activator inhibitor-1 (PAI-
1), 8-isoprostane, and thiobarbituric acid reactive substances (TBARS).
Thirty one patients completed the study. More of the drop outs occurred in subjects receiving aliskiren. Systolic blood
pressure decreased in both treatment arms with no differences between groups being noted. PAI-1, NO, and CRP concentrations
increased in both groups from baseline but changes from baseline or between groups were not significant. VCAM, ICAM, TBARS,
and isoprostane concentrations decreased in each treatment arm from baseline but these changes were not significant and no
differences between groups were noted.
Treatment with either aliskiren or amlodipine did not significantly alter surrogate biomarkers of atherosclerosis
in patients with both diabetes and established cardiovascular disease already receiving appropriate secondary cardiovascular
prevention therapy. The study is limited in its size and duration to see an effect.
Brian K. Irons is an Associate Professor and Division Head-Ambulatory Care at the Texas Tech University Health Sciences Center School of
Pharmacy. He has been on faculty there since 1999. He completed both a PGY-1 and PGY-2 residency after completing his BS and PharmD from the
University of Wisconsin. Dr. Irons has over 35 publications most of which are in the area of management of type 2 diabetes mellitus. He is a Fellow
with the American College of Clinical Pharmacy.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals